medigraphic.com

2015, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (4)

Prevalence of metabolic syndrome and insulin resistance in system sclerosis

Peralta-Amaro AL, Cruz-Domínguez MP, Olvera-Acevedo A, Vera-Lastra OL

Language: Spanish
References: 33
Page: 476-483
PDF size: 373.34 Kb.


ABSTRACT

Background: The metabolic syndrome (MS) is a group of cardiovascular risk factors whose prevalence is increased in rheumatic diseases. The aim of this study was to estimate de prevalence of MS and insulin resistance (IR) in systemic sclerosis (SSc).
Methods: Fifty five patients with SSc were included. The World Health Organization criteria were used to define MS. Demographic, anthropometric and blood pressure data were recorded. Blood glucose, high density lipoprotein cholesterol (HDL-c), triglycerides and insulin were measured. Oral glucose tolerance curve was performed to identify impaired glucose tolerance and diabetes mellitus in those patients with normal fasting blood glucose. The HOMA index was calculated as well as a quantified proteinuria in urine of 24 hours.
Results. The prevalence of MS was 36.4 % (20 of 55 patients). Seventy percent of the patients with MS had limited SSc and 30 % diffuse SSc. An increased IR was observed in the limited SSc in comparison with the diffuse SSc (2.948 vs. 1.817 ± 0.3844 ± 0.2771, p = 0.03). An association between IR and MS was found in the limited SSc (p = 0.0001). Regarding the rest of the MS criteria, hypertriglyceridemia and an abnormal waist/ hip ratio were the variables most often encountered, 95 % and 85 % respectively. Fifty percent of MS patients had low levels HDL-c and 40 % of them were hypertensive. None of the patients had proteinuria.
Conclusions: The prevalence of MS in SSc was 36.4 %, similar to the found in other rheumatic diseases, but higher compared to the found in the Mexican population.


REFERENCES

  1. Vera Lastra O. Esclerosis sistémica. Med Int Mex. 2006;22:231-45.

  2. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 2001; 28(7):1573–76.

  3. Boin F, Hummers L. Scleroderma-like Fibrosing Disorders. Rheum Dis Clin N Am. 2008;34: 199–220.

  4. Ausiello D, Benos D, Abboud F, et. al. Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis. Ann Intern Med. 2004;140:37-50.

  5. Agarwal S, Tan F, Arnett F. Genetics and Genomic Studies in Scleroderma (Systemic Sclerosis). Rheum Dis Clin N Am. 2008;34:17–40.

  6. Nietert P, Silver R. Systemic sclerosis: environmental and occupational risk factors. Current Opinion in Rheumatology. 2000;12:520-526.

  7. Boin F, Hummers L. Scleroderma-like Fibrosing Disorders. Rheum Dis Clin N Am. 2008;34: 199–220.

  8. Sidiropoulos P, Karvounaris S, Boumpas D. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Research & Therapy 2008;10:1-9.

  9. Eckel R, Grundy S, Zimmet P. The metabolic syndrome. Lancet 2005;365:1415-28.

  10. Burner T, Rosenthal A. Diabetes and rheumatic diseases. Current Opinion in Rheumatology. 2009;21: 50–54.

  11. Lerman Garber I, Aguilar-Salinas C, Gómez-Pérez F, et. al. El síndrome metabólico. Características del síndrome metabólico en México. Revista de Endocrinología y Nutrición. 2004;12(3):109-122.

  12. Muniyappa R, Iantorno M, Quon M, et. al. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin N Am. 2008;37: 685-711.

  13. Malesci D, Valentini G, La Montagna G. Metabolic syndrome in inflammatory rheumatic diseases. Reumatismo. 2006;58(3):169-76.

  14. Gore-Hyer E, Pannu J, Smith E, et. al. Selective Stimulation of Collagen Synthesis in the Presence of Costimulatory Insulin Signaling by Connective Tissue Growth Factor in Scleroderma Fibroblasts. Arthritis Rheum. 2003;48(3):798-806.

  15. Boise W, Wajchenberg BL, Moncada VY, Marcus- Samuels B, Taylor si. Atypical antiinsulin receptor antibodies in a patient with type B insulin resistance and scleroderma. J Clin Endocrinol Metab. 1989;68 (1):227-31.

  16. Graffigna N, Litwak L, Abdala M, et. al. Determinación del índice homa en sujetos presuntamente sanos. Estudio epidemiológico multicéntrico. RAEM. 2005;42(1):12-19.

  17. Aguilar-Salinas C, Rojas R, Gomez-Perez F, et. al. Analysis of the agreement between the World Healt Organization Criteria and the National Cholesterol Education Program-III definitions of the metabolic syndrome: Results from a population-based survey. Diabetes Care. 2003;26(5):1635.

  18. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2765-75.

  19. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008; 196(2):756-63.

  20. Chung C, Oeser A, Solus J, et. al. Inflammationassociated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythemato sus define potential mechanisms. Arthritis Rheum. 2008;58(7):2105-2112.

  21. Zonana-Nacach A, Santana-Sahagún E, Jiménez- Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol. 2008;14 (2):74-7.

  22. Chung C, Avalos I, Oeser A, et. al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Annals of the Rheumatic Diseases. 2007:66(2):208-214.

  23. Sada KE, Yamasaki Y, Maruyama M, et. al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol. 2006;33(8): 1545-52.

  24. Negrón AM, Molina MJ, Mayar AM, Rodríguez VE, Vilá LM. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus. 2008;17(4):348-54.

  25. Bellomio V, Spindler A, Lucero E, Berman A, Sueldo R, Berman H, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus. 2009;18(11):1019-25.

  26. Magadmi M, Ahmad Y, Turkie W, et. al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006;33(1):50-6.

  27. Kahan A, Allanone Y. Primary myocardial involvement in systemic sclerosis. Rheumatology 2006;45: 14-17.

  28. Azfara RS and Gelfanda JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Current Opinion in Rheumatology. 2008; 20:416-422.

  29. Chakraborty C. Biochemical and molecular basis of insulin resistance. Current Protein and Peptide Science. 2006;7:113-121.

  30. Petersen K, Shulman G. Etiology of insulin resistance. The American Journal of Medicine. 2006; 119:10S-16S.

  31. Shoelson S, Lee J, Goldfine A. Inflammation and insulin resistance. Clin. Invest. 2006;116:1793–1801.

  32. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg. 2008;70(3):193-219.

  33. Hivert MF, Sullivan L, Fox C, et. al. Associations of Adiponectin, Resistin, and Tumor Necrosis Factora with Insulin Resistance. J Clin Endocrinol Metab. 2008;93:3165-72.




2020     |     www.medigraphic.com